# Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract

> **NCT01564017** · PHASE2 · COMPLETED · sponsor: **Roxall Medicina España S.A** · enrollment: 150 (actual)

## Conditions studied

- Allergic Rhinoconjunctivitis

## Interventions

- **BIOLOGICAL:** Allergovac depot
- **BIOLOGICAL:** Allergovac depot
- **BIOLOGICAL:** Allergovac depot
- **BIOLOGICAL:** Allergovac depot
- **BIOLOGICAL:** Allergovac depot
- **BIOLOGICAL:** Allergovac depot

## Key facts

- **NCT ID:** NCT01564017
- **Lead sponsor:** Roxall Medicina España S.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2017-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01564017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01564017, "Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01564017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*